NEWS
-
2024/07/22 Correctseq
The First Clinical Gene Editing Therapy to Treat An Overseas Patient in China
On July 20, 2024, Shanghai, China, CorrectSequence Therapeutics Co., Ltd. (Correctseq) announced a significant milestone in their base editing therapy CS-101 for transfusion-dependent β-thalassemia. U
-
2024/07/19 Correctseq
CS-101 Clinical Result Included in EHA2024 Scientific Congress Report
Recently, the European Hematology Association (EHA) released the EHA2024 Scientific Congress Report titled "EHA Perspectives on Emerging Technologies in Hematology". As the world's firs
-
2024/06/06 Correctseq
CorrectSequence Therapeutics to Participate in EHA2024 Hybrid Congress
June 6, 2024, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aims to use the innovative gene editing technology to help people with severe diseases, announ
-
2024/06/03 Correctseq
CorrectSequence Therapeutics to Participate in BIO International Convention 2024
May 29, 2024, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aims to use the innovative gene editing technology to help people with severe diseases, announ
-
2024/04/13 Correctseq
April 12, 2024, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aims to use the innovative gene editing technology to help people with severe diseases, anno
-
2024/04/02 Correctseq
CorrectSequence Therapeutics’ (Correctseq’s) base editing drug "CS-101 Injection" targeting transfusion-dependent β-thalassemia has obtained IND approval from the National Medical Products Administration (NMPA) of China on April 2, 2024 (acceptance number: CXSL2400021). This is the Chinese first base editing therapy with β-thalassemia. Correctseq is initiating the Phase 1 clinical study for CS-101 (clincialtrials.gov reference # NCT06291961).
-
2024/01/16 Correctseq
January 17-19, 2024, PST, the 5th International Conference on Base Editing, Prime Editing & Related Enzymes will be held at San Diego, California. Dr. Jia Chen, Professor of ShanghaiTech University, Co-founder of CorrectSequence Therapeutics will participate in this conference and give an oral presentation titled” Therapeutic base editing for β-thalassemia” on Jan. 17, at 5:05 - 5:20 pm, PST.
-
2024/01/08 Crectseq
The World’s First Clinical Base Editing Therapy for Hemoglobinopathy
On January 8, 2024, Shanghai, China, CorrectSequence Therapeutics Co., Ltd. (Correctseq), using innovative transformer Base Editing (tBE) technology to help people with severe diseases, announced positive results of its base editing therapy for transfusion-dependent β-thalassemia, CS-101. As a collaboration with the First Affiliated Hospital of Guangxi Medical University, the Investigator-Initiated Trial (IIT) of CS-101 has successfully cured the first treated patient with transfusion-dependent β-thalassemia, resulting in sustained transfusion-free for more than two months.